ARS Pharmaceuticals, Inc. SPRY Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s net income?
- ARS Pharmaceuticals, Inc. (SPRY) reported net income of -$60.62M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s net income changed year-over-year?
- ARS Pharmaceuticals, Inc.'s net income decreased by 78.6% year-over-year, from -$33.94M to -$60.62M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s net income?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s net income has grown at a 70.3% compound annual growth rate (CAGR), from -$34.68M to -$171.3M.
- What does net income mean?
- Net income as the starting point for the indirect method operating cash flow reconciliation.